Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
Allergic RhinitisConjunctivitis
Interventions
DRUG

REGN5713

Administered subcutaneously

DRUG

REGN5714

Administered subcutaneously

DRUG

REGN5715

Administered subcutaneously

DRUG

Placebo

Placebo that replaces REGN5713-5714-5715

Trial Locations (37)

2650

Regeneron Study Site, Hvidovre

2900

Regeneron Study Site, Hellerup

3000

Regeneron Study Site, Leuven

7100

Regeneron Study Site, Vejle

9000

Regeneron Study Site, Ghent

10117

Regeneron Study Site, Berlin

11021

Regeneron Study Site, Great Neck

14050

Regeneron Study Site, Berlin

15241

Regeneron Study Site, Pittsburgh

21224

Regeneron Study Site, Baltimore

22549

Regeneron Study Site, Hamburg

40225

Regeneron Study Site, Düsseldorf

43617

Regeneron Study Site, Toledo

45231

Regeneron Study Site, Cincinnati

47051

Regeneron Study Site, Duisburg

53228

Regeneron Study Site, Greenfield

55441

Regeneron Study Site, Plymouth

59808

Regeneron Study Site, Missoula

63141

Regeneron Study Site, St Louis

63303

Regeneron Study Site, Dreieich

65183

Regeneron Study Site, Wiesbaden

65212

Regeneron Study Site, Columbia

69120

Regeneron Study Site, Heidelberg

70374

Regeneron Study Site, Stuttgart

97202

Regeneron Study Site, Portland

04401

Regeneron Study Site, Bangor

07044

Regeneron Study Site, Verona

02865

Regeneron Study Site, Lincoln

K7L 2V7

Regeneron Study Site, Kingston

N5W 6A2

Regeneron Study Site, London

K1G 6C6

Regeneron Study Site, Ottawa

M4V 1R2

Regeneron Study Site, Toronto

M5B 1W8

Regeneron Study Site, Toronto

M5G 1E2

Regeneron Study Site, Toronto

G8T 7A1

Regeneron Study Site, Trois-Rivières

G1V 4M6

Regeneron Study Site, Québec

01139

Regeneron Study Site, Dresden

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04709575 - Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter